TAILIEUCHUNG - ESPON 2013 DATABASE INCEPTION REPORT

RIATE has download most basic social, economic and demographic data available in NUTS2003 division in 2007, just before the moment where EUROSTAT change its website and adopted the new NUTS2006 division. At this moment, the regional datasets was generally complete for all countries with most recent information on years 2005 or 2006. UAB has produced recently for EEA an application that convert Corine Land Cover 1990 and 2000 into NUTS2003 units NUTS3 level. This data are therefore immediately available for use and can be combined with socio-economic data collected by RIATE. . | ESPON 2013 DATABASE - Inception Report - 26 Sept. 2008 ESPON 2013 DATABASE INCEPTION REPORT 26 September 2008 H EUROPEAN UNION Part-financed by the European Regional Development Fund INVESTING IN YOUR FUTURE 1 This inception report represents the first results of a research project conducted within the framework of the ESPON 2013 programme partly financed through the INTERREG III ESPON 2013 programme. The partnership behind the ESPON Programme consists of the EU Commission and the Member States of the EU25 plus Norway Switzerland Iceland and Liechteinstein. Each country and the Commission are represented in the ESPON Monitoring Committee. This report does not necessarily reflect the opinion of the members of the Monitoring Committee. Information on the ESPON Programme and projects can be found on The web site provides the possibility to download and examine the most recent document produced by finalised and ongoing ESPON projects. ISBN number This basic report exists only in an electronic version. Word version The ESPON Monitoring Committee and the partners of the projects mentioned. Printing reproduction or quotation is authorized provided the source is acknowledged and a copy is forwarded to the ESPON Coordination Unit in Luxembourg. ESPON 2013 DATABASE - Inception Report - 26 Sept. 2008 List of contributors to the inception report UMS RIATE FR Claude Grasland Ben Rebah Maher Christine Zanin Nicolas Lambert Bernard Corminboeuf Chloe Didelon LIG-IMAG FR Jérôme Gensel Bogdan Moisuc Christine Plumejeaud UAB ES Andreas Littkopf Juan Arevalo IGEAT BE Moritz Lennert UMR Géographie-cités FR Anne Bretagnolle Hélène Mathian Joel Boulier Timothée Giraud Marianne Guerois TIGRIS RO Octavian Groza Université du Luxembourg LU Geoffrey Caruso Scientific coordinators of the project

• Cơ sở dữ liệu
• Drug treatment
• short course
• treatment failure
• health and nutrition
• education
• gen
• Tạp chí khoa học
• Tạp chí y dược
• Y dược quân sự
• Drug resistance
• First line antiretroviral treatment failure
• Genetic mutation for drug resistance
• Bài viết nghiên cứu khoa học
• Drug treatment of dyslipidemia
• Military Hospital 105
• Patients' LDL C
• renal drug treatment of kidney disease
• kidney treatment
• kidney disease prevention
• Approved Drug Products
• Approved Drug
• BMC Cancer
• Oncology clinical trial drug interaction
• Increased risk
• Drug drug interactions
• Increase treatment toxicity
• Descriptive statistics
• BMC Genomics
• Drug resistant tuberculosis
• Genetic changes
• Pre extensively drug resistant
• Cardiovascular pharmacotherapeutics
• Complementarymedicine for preventing
• Treatingcardiovascular disease
• Cardiovascular drug–drug interactions
• Drug treatment of peripheral vascular disorders
• Cardiovascular drugs in development
• Pediatric cardiovascular pharmacology
• Adolescent psychiatry
• Mental health
• Adverse drug events
• Therapeutic drug monitoring
• Drug naïve population
• Child psychiatry
• aids
• hiv
• china
• guangxi
• province
• confinement
• mandatory
• cycle
• drug
• dependency
• treatment
• BMC Pulmonary Medicine
• Multi drug resistant tuberculosis
• Standard short course chemotherapy
• Acquired drug resistant tuberculosis emergence
• Multivariate logistic regression;
• Methods employed
• Diagnosis of pulmonary
• Clinical diagnosis
• Neonatal abstinence syndrome
• Disorder treatment access
• Public health
• Outpatient treatment programs
• Drug withdrawal syndrome
• new drug regimens
• Expanded discussion
• Drug information
• bibliographies
• medicine
• complementary therapies
• antiphospholipid syndrome
• lipid disorders
• Polysaccharides for Colon
• Targeted Drug Delivery
• Improved Drug
• Release Specificity
• Therapeutic Benefits
• Factors in Pathogenesis
• Preparation of cellulose coated hydrogels
• Controlled drug release
• Cellulose coated microparticles
• Cross linkage treatment
• Harmful and sophisticated
• ABC of epilepsy
• Classifying the condition
• Making the diagnosis
• Clinical examination
• Managing the drug treatment
• Repeated seizures
• Non drug treatments including epilepsy surgery
• Breast cancer
• Computational framework
• Drug repurposing
• Dynamic gene expression
• Entering clinical trials
• Hepatocellular carcinoma
• Conventional transarterial chemoembolization
• Drug eluting bead transarterial chemoembolization
• According to mRECIST
• Palliative treatments
• BMC Pediatrics
• Introduction of antiretroviral therapy
• Treatment of paediatric HIV infection
• Drug intake logistics
• Therapeutic failure
• BMC Pharmacology and Toxicology
• Type 2 diabetes mellitus
• Peripheral edema
• Weight gain
• Antihypertensive drug therapy
• Prospective study
• Blood pressure
• Calcium channel blockers
• Drug screen
• Cell fate
• Extracellular matrix
• RAF inhibitor
• MAPK pathway
• BMC Molecular and Cell Biology
• Epidermal growth factor receptor
• EGFR signaling
• Signaling crosstalk
• Geometric properties
• Tuberculosis